Contraindications for Thrombolysis in Pulmonary Embolism
In high-risk PE with shock or persistent hypotension, most contraindications become relative rather than absolute, and thrombolysis should be administered unless there is active bleeding or recent hemorrhagic stroke. 1, 2
Absolute Contraindications
The following are considered absolute contraindications in most clinical contexts 1, 2:
- Hemorrhagic stroke or stroke of unknown origin at any time - This remains an absolute contraindication even in life-threatening PE 1, 2
- Ischemic stroke within the preceding 6 months 1, 2
- Central nervous system damage or neoplasms 1, 2
- Recent major trauma, surgery, or head injury within the preceding 3 weeks 1, 2
- Gastrointestinal bleeding within the last month 1, 2
- Known active bleeding disorder 1, 2
Relative Contraindications
These contraindications require careful risk-benefit assessment, particularly in high-risk PE 1, 2:
- Transient ischemic attack in preceding 6 months 1, 2
- Current oral anticoagulant therapy 1, 2
- Pregnancy or within 1 week postpartum 1, 3, 2
- Non-compressible vascular punctures 1, 2
- Traumatic cardiopulmonary resuscitation 1, 2
- Refractory hypertension (systolic blood pressure >180 mmHg) 1, 2
- Advanced liver disease 1, 2
- Infective endocarditis 1, 2
- Active peptic ulcer disease 1, 2
Critical Context: High-Risk vs. Non-High-Risk PE
The severity of PE fundamentally changes how contraindications are interpreted 1, 4:
High-Risk PE (Shock/Persistent Hypotension)
- Contraindications that are absolute in acute myocardial infarction (such as surgery within 3 weeks or GI bleeding within the last month) become relative in immediately life-threatening high-risk PE 1, 2
- The survival benefit of thrombolysis in hemodynamically unstable patients outweighs most bleeding risks 4, 5
- Thrombolysis should be administered unless there are very few absolute contraindications (primarily active hemorrhage or recent hemorrhagic stroke) 1, 5
Intermediate-Risk PE (RV Dysfunction Without Shock)
- Standard contraindications apply more strictly 1
- Thrombolysis may be considered in selected patients without contraindications, but routine use is not recommended 1
- The bleeding risk (13% major bleeding, 1.8% intracranial/fatal hemorrhage) must be carefully weighed against uncertain benefit 1
Low-Risk PE
Bleeding Risk Considerations
Major bleeding occurs in approximately 13% of patients receiving thrombolysis, with intracranial or fatal hemorrhage in 1.8% 1. Risk factors that increase bleeding complications include 3, 6:
- Recent surgery (within 7 days)
- History of peptic ulcer disease or GI/urinary tract bleeding
- Platelet count <150 × 10⁹/L
- Invasive vascular procedures within 7 days
- Prolonged cardiopulmonary resuscitation
Alternative Strategies When Thrombolysis is Contraindicated
When absolute contraindications exist in high-risk PE 1, 2, 7:
- Surgical pulmonary embolectomy is the preferred alternative 1, 2
- Catheter-based embolectomy or thrombus fragmentation may be considered if surgery is not immediately available 1, 2, 7
- Low-dose prolonged thrombolysis (e.g., urokinase 1,000 units/kg/h) has been reported as an alternative when standard doses are contraindicated, though this is not guideline-recommended 8
Important Caveats
- Recent thrombolysis is not a contraindication to surgical embolectomy if thrombolysis fails 1
- Angiographic confirmation is no longer required before thrombolysis and actually increases bleeding complications 4
- In pregnancy, thrombolysis is appropriate for massive PE but contraindicated within 6 hours of delivery due to extreme bleeding risk 3
- The choice between alteplase, tenecteplase, or catheter-directed therapy should favor alteplase in standard dosing (100 mg over 2 hours) as it shows lower major bleeding rates compared to tenecteplase or catheter-directed approaches 9